3rd Line and beyond

You are here

3rd Line and beyond

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Case Based Panel Discussion - What is the Optimal Approach for a Fit Patient with Advanced Squamous NSCLC and Low Tumor PD-L1 Expression
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal approach for a fit patient with advanced squamous NSCLC and low tumor PD-L1 expression.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Chemotherapy, Immunotherapies, Adjuvant Therapy, 3rd Line and beyond, Targeted Therapy
Lung Cancer Video Library - Immunotherapy for Previously Treated Patients with NSCLC
Dr. Karen Reckamp, MD, MS, City of Hope Comprehensive Cancer Center in Duarte, California joined GRACE to discuss the role of immunotherapy for previously treated patients with non-small cell lung cancer.
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
3rd Line and beyond, Second-line treatment, Immunotherapies
,
,
Targeted Therapies in Lung Cancer Patient Forum 2017 - Presentations and Handouts
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
Cancer Journey:
Just Diagnosed, In Treatment, Survivorship
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Tumor Marker Tests, 3rd Line and beyond, Targeted Therapy, Molecular Testing, First-line treatment, Scans - PET-CT, etc., Second-line treatment, Clinical Trials, Non Small Cell Lung Cancer
What are the Goals of Treating Advanced NSCLC?
Transcript I think there are several goals when treating a patient with advanced non-small cell lung cancer. For one I think we want to extend life,...
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Chemotherapy, First-line treatment, Molecular Testing, Targeted Therapy, Maintenance Therapy, Symptoms, Second-line treatment, 3rd Line and beyond
HER2 Mutation Positive NSCLC
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Clinical Trials, Molecular Testing, Targeted Therapy, 3rd Line and beyond, Second-line treatment

Articles

The Risk of Overtreating Indolent Bronchioloalveolar Carcinoma
From the Grace Archives | Originally P ublished December 6, 2006 | By Dr West | 25 Comments Bronchioloalveolar carcinoma, or BAC , is a subtype of...
Cancer Journey:
Just Diagnosed, In Treatment, In Remission, Survivorship
Cancer Type:
Lung Cancer
Disease Learning:
First-line treatment, Second-line treatment, 3rd Line and beyond, Biopsy/Tissue Collection
Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko
Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, First-line treatment, Molecular Testing, Maintenance Therapy, Second-line treatment, 3rd Line and beyond
The Perils of Molecular Oncology: Mutations Aren't Everything, or at Least They're Not Infallible
Every few months I see a patient who reminds me of the fallability of mutation testing. One of the brightest rays of hope in the management of lung...
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Molecular Testing, Symptoms, Second-line treatment, 3rd Line and beyond
MARQUEE Trial of MET Inhibitor Tivantinib (ARQ-197) Negative for Survival Benefit, But OS Benefit Seen in MET-Positive Patients
Almost exactly a year ago, I reported that the large MARQUEE trial of EGFR inhibitor Tarceva (erlotinib) plus either the MET inhibitor tivantinib (...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Second-line treatment, 3rd Line and beyond
Afatinib for Patients with Acquired Resistance to EGFR TKIs? Perhaps in Combination with Erbitux, but Is It Tolerable?
With the recent approval of afatinib, now becoming commercially available as Gilotrif, there is the potential new strategy for patients with an EGFR...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Second-line treatment, 3rd Line and beyond

Community Forum

Videos now posted! OncTalk 2018 - Local Therapies for Metastatic Lung Cancer - Who, What, Why, When and How?
On Saturday, November 10, 2018, GRACE partnered with Swedish Cancer Institute to present a live and webcast discussion on Local Therapies for...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Lung Cancer, General Lung Cancer, Chemotherapy, 3rd Line and beyond, Scans - PET-CT, etc., Surgical, Immunotherapies, Radiation Therapy, Non Small Cell Lung Cancer
Vaxira for stage 4 NSCLC
Has anyone any information on obtaining and using Vaxira, the Cuban drug, for stage 4 advanced NSCLC? Not sure if US citizens can still travel to...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
ANGIOGENESIS, 3rd Line and beyond, Targeted Therapy, Investigational Agents, Non Small Cell Lung Cancer